In the peritoneal carcinomatosis model, the Agpat4 silencing-induced suppression of CRC progression was fully prevented by the combined treatment with antibodies against IL1β and IL-6 (Fig. 5f). This evidence concerns the gene IL1B and colorectal carcinoma.